Imaging biomarkers for AD and MCI include both positron emission tomography (PET) (e.g., using amyloid and tau tracers) and magnetic resonance imaging (MRI) methods, the latter of which are used to assess structural, microstructural, and other pathophysiological characteristics of AD [5]. Here, MAPT is linked to Alzheimer disease.